Navigation Links
CytoVas And BD Biosciences Ink Alliance To Co-Develop Personalized Diagnostic For Vascular Health

PHILADELPHIA, April 25, 2013 /PRNewswire-iReach/ -- CytoVas, LLC and BD Biosciences, a division of BD (Becton,  Dickinson and Company), announced today they have formed a strategic alliance to jointly develop a new blood-based diagnostic test to predict individualized patient risk of heart attack and stroke. 

This test, currently called the Vascular Health Profile (VHP), fills a major unmet need in cardiovascular medicine.  Atherosclerotic cardiovascular disease (CVD) affects over 82 million people in the US and remains the leading cause of death throughout the developed world.  In the next few years worldwide CVD-related complications and costs are expected to dramatically increase coincident with the growing prevalence of diabetes.  Despite this immense and increasing demand, no reliable predictive measure exists to help physicians stratify risk for individual patients and optimize decisions for therapeutic intervention and management. 

"The Vascular Health Profile offers a critical advance in cardiovascular care," said Emile Mohler , MD, a cardiologist and Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania and a co-inventor of the technology.  "As cholesterol testing has been shown non-predictive of true health outcomes, we need a test that can accurately guide therapeutic decision-making."

CytoVas, LLC was founded under the University of Pennsylvania UPstart incubator program by Jonni S. Moore , PhD, and Wade Rogers , PhD, of the Department of Pathology and Laboratory Medicine, along with Dr. Mohler, all faculty members of the Perelman School of Medicine at the University of Pennsylvania.  In May 2012, the American Heart Association (AHA) announced CytoVas would become the first recipient of funding through their Science & Technology Accelerator Program, an initiative designed to speed the investigation and development of products to help people with cardiovascular disease.

"In the current landscape, it's not easy for research discoveries to forge a rapid path toward patient benefit," said Dr. Moore, a world-renowned expert in flow cytometry, Professor of Pathology and Laboratory Medicine, and Director of Clinical and Research Flow Cytometry at the Perelman School of Medicine. "The partnership with BD is a promising step in bridging the gap from research to patients for this potentially life-saving diagnostic."  

The partnership enables CytoVas to investigate the Vascular Health Profile's capacity to assess cardiovascular disease progression, as well as the cardiovascular-related efficacy and side effect profiles of existing and experimental medicines.  The Company already has studies underway with several therapies to that end.

"I believe the VHP will become instrumental in guiding treatment decisions by helping us understand what is happening – in real time – at the actual site of a patient's atherosclerotic plaque, the endothelium," said Noel Warner , PhD, Worldwide Vice President, Scientific Affairs, BD Biosciences.  "This could be instrumental in guiding clinical treatment as well as aiding industry as a biomarker or companion diagnostic for therapeutic innovation." 

"For the American healthcare system, the Vascular Health Profile is a potential game-changer," said Ross Tonkens , a cardiologist and head of the American Heart Association's Science & Technology Accelerator Fund.  "This test not only offers the promise of identifying symptom-free individuals at high risk, but could also assess the effectiveness of new therapies to prevent heart attack and stroke."

Cytovas and BD expect their current strategic alliance to run for at least two years, at the end of which they will consider options to gain regulatory and reimbursement approval to market the Vascular Health Profile.

About CytoVas

CytoVas is a leading-edge biomarker discovery and development company based in Philadelphia.  The company's patent-pending Cytometric Fingerprinting technology automates pattern recognition of known cellular markers of disease and treatment over time and across broad patient populations.  The technology was developed by a team of University of Pennsylvania scientists and physicians and spun out of the UPstart Program at the University's Center for Technology Transfer in 2011.  The Company's first focus area for research, Cardiovascular Health, used the new science of cytomics to combine sensitive laser-based flow cytometry measurements with unique computational methods to discover a pattern, or profile, that can reflect the health of the endothelium.  For more information, please visit

Media Contact:

Todd Johnson CytoVas, 917-750-9605,

News distributed by PR Newswire iReach:

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
2. Chipscreen Biosciences Announces Achievement of Primary Endpoint in Chidamide Registrational Trial in China
3. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
4. Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
5. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
6. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
7. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
8. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
9. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
10. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
11. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
Post Your Comments:
(Date:10/13/2015)... Fla. , Oct. 13, 2015   Vigilant ... of solutions that aid in the early detection and ... has awarded Vigilant,s founder and CEO, Matthew H.J. ... Year Award, which recognizes an entrepreneur who has made ... life sciences industry in the leadership of ...
(Date:10/13/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... serving the pharmaceutical, biotechnology, and medical device industries, ... version of OncoWuXi, the first App in the ... and data on the go.  The OncoWuXi App ... to identify relevant tumor models for use in ...
(Date:10/13/2015)... 13, 2015   Happy Vitals ®, ... home testing kit for breast milk.  The ... an unparalleled, detailed assessment of the nutrition ... carbs and key vitamins—all charted over time ... health tracking.  In addition, Happy Vitals also offers ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood ... 2015. The research, which was conducted at the Dental Institute at King's College London ... between stress during pregnancy and future dental health in the child. For years, researchers ...
(Date:10/13/2015)... ... October 13, 2015 , ... Protein is essential to good health. ... bone, and blood. But how much protein does the average man need in order ... according to the October 2015 issue of Harvard Men's Health Watch . Most ...
(Date:10/13/2015)... Waycross, GA (PRWEB) , ... October 13, 2015 ... ... charitable nonprofit promoting the establishment of telemedicine programs in communities throughout Georgia, along ... (FTP) announce the collective schedule for their regional telehealth summits for Fall 2015. ...
(Date:10/13/2015)... ... 13, 2015 , ... According to an ESPN report published on ... teammate accidentally elbowed him in the left eye during the first day of practice ... of a series of setbacks, including a knee injury that has interfered with his ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an ongoing effort ... , a Southlake, Texas, child development and pediatric therapy center, is working with ... families about their options for receiving this kind of care for affected children. ...
Breaking Medicine News(10 mins):